Allogene Therapeutics

This week in UC Berkeley's CBE 298B Seminar in Bioprocess Engineering, our students were joined by Ben Beneski of Allogene Therapeutics for an afternoon of scaling cell therapy for the future. Based in South San Francisco with manufacturing facilities in nearby Newark, Allogene is a clinical-stage biotechnology company focused on the development of investigational allogeneic chimeric antigen receptor T cell (= AlloCAR T) products for cancer & autoimmune disease. To this end, Ben & his colleagues are developing a pipeline of off-the-shelf CAR T candidates with the goal of delivering readily available cell therapies faster, more reliably, and at a greater scale to more patients. Ben began with the basics of CAR T therapies: T cells are white blood cells (lymphocytes) that fight infections & protect our bodies from disease. In the case of allogeneic CAR T technology, T cells are taken from healthy donors & modified with a chimeric antigen receptor (CAR) protein to help them seek & destroy cancer cells. These CAR T cells are then given intravenously to sick patients to treat the underlying disease. From process to scalable CAR T product, Ben took our aspiring bioprocess scientists & engineers through the critical stages of process & analytical development, quality & product characterization, manufacturing, and supply chain management - all linked through deep product understanding. Along the way, he emphasized the value of process characterization to quantify variability & drive a comprehensive manufacturing control strategy (something our students are learning in their CBE 275 Advanced Bioprocess Engineering course!). Ben closed our highly interactive session with a case study on ALLO-329, a dual CD19/CD70 targeting CAR T therapy uniquely engineered for a broad set of autoimmune diseases. A BIG THANKS (!!!) to Ben & Allogene for sharing process engineering best practices for next-generation CAR T therapies! We also hope you enjoyed your first visit & tour of UC Berkeley's campus featuring historic Lewis, Latimer & Gilman Halls; the iconic Campanile; and (of course!) Sather Gate 😊 GO BEARS!!! 🐻💙💛 UC Berkeley Master of Bioprocess Engineering #ucberkeley #biomanufacturing #bioprocessing #biopharma #biotechnology #biotherapeutics #cart #celltherapy

🧬 What a jam-packed afternoon on Day 1 of the American Biomanufacturing Summit (biomanamerica.com)! The momentum didn’t slow down as the day progressed—bringing even deeper insights, collaboration, and innovation to this sunny day at the Hyatt Regency San Francisco Airport ☀️ Conversations continued across #bioprocessing, cell & gene therapy, manufacturing scale-up, and regulatory strategy—uniting leaders driving progress across the biopharma landscape. Some highlights from this afternoon’s sessions include: 🔹 Sheena Behn, VP, Vaccine and Immune Therapy and Oncology Global Supply at AstraZeneca — presenting “Scaling Supply Chains for Advanced Therapies to Meet Global Patient Needs.” 🔹Farah Fawaz, SVP, Quality and Compliance at Allogene Therapeutics — delivering the session “Ensuring End-to-End Product Excellence: Integrating Quality Attributes Across the Cell Therapy Lifecycle.” 🔹 An engaging panel featuring leaders from Kite Pharma, Bristol Myers Squibb, Allogene Therapeutics, Eli Lilly and Company, and Johnson & Johnson — discussing “From Innovation to Execution: Enabling Scalable Agile and Tech Forward Biomanufacturing.” + many more! From advancing #CGT manufacturing and optimizing bioprocesses to navigating compliance and supply chain challenges, the afternoon sessions showcased what it takes to advance operations across biomanufacturing. With more insights, networking, and collaboration ahead on Day 2, the conversations are just getting started! 🔗 Learn more: https://biomanamerica.com/ — #GenerisBIO #BIOUS26 #Biomanufacturing #Biopharma #Biotech #CellAndGeneTherapy #CGT #Bioprocessing #LifeSciences

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated patients in the study’s first data drop. https://lnkd.in/gdKVkqS9

Allogene Therapeutics’ gamble on a never-before-seen trial strategy seems to be paying off, with the biotech’s off-the-shelf cell therapy eradicating residual lymphoma in over half of evaluated patients in the study’s first data drop. https://lnkd.in/gdKVkqS9